<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659347</url>
  </required_header>
  <id_info>
    <org_study_id>DOV 947-010</org_study_id>
    <nct_id>NCT00659347</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DOV 21,947 in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DOV Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DOV Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this placebo-controlled trial are to evaluate effectiveness and
      safety of DOV 21,947 at two oral dose levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DOV 21,947 is an investigational drug that is being developed for the treatment of
      depression. The purpose of this study is to evaluate the safety and effectiveness of a
      flexible dosing schedule of DOV 21,947 (25 mg twice daily for two weeks, then 50 mg twice
      daily for four weeks as compared to placebo) in the treatment of major depressive disorder.
      Information about any side effects that may occur will also be collected.

      The efficacy evaluation will be based on the change in the total MADRS and HAMD-17 scores
      from randomization to week 9 .The secondary objective is to determine if DOV 21,947 improves
      the quality of life for patients with MDD as compared to placebo
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure will be the change in tot al score of MADRS scale.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOV 21, 947</intervention_name>
    <description>Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules,25 mg,BID,6weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between 18 and 65 years of age (inclusive).

          2. Either outpatients or inpatients diagnosed with major depressive disorder (MDD)
             according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR, see
             Appendix 3) and MINI International Neuropsychiatric Interview (MINI).

          3. Patients with recurrent depressive episode of at least 2 months in duration. Patients
             must have previously responded (significant clinical improvement judged by the
             Principal Investigator) to at least one antidepressant treatment.

          4. HAMD-17 total score * 22 with a severity score of at least 2 on Item 1 at the Placebo
             Run-In Visit and the Baseline/Day 1 Visit.

          5. HAMD-17 score reduction â‰¤ 15% between the Placebo Run-In Visit and the Baseline/Day 1
             Visit.

          6. HAM-A total score &lt; 17 at the Screening Visit.

        Exclusion Criteria:

          1. Patients with a HAMD-17 total score reduction of more than 15% between the Placebo
             Run-In Visit and the Baseline/Day 1 Visit (placebo responders).

          2. Patients with a medical history of MDD that consistently did not respond significantly
             to an adequate treatment regimen of a monoamine oxidase (MAO) inhibitor.

          3. Patients who are known to be antidepressant treatment-resistant. Patients are defined
             as treatment-resistant if in the past they have failed adequate antidepressant
             treatments (dose level approved in the product labeling and was administered for at
             least 4 weeks) from two or more different pharmacological classes (e.g., TCA, SSRI,
             SNRI, MAO-I, etc). Failure to respond to an adequate antidepressant treatment is
             defined as the absence of at least a 50% improvement in symptoms by patient report or
             documented history, or lack of significant clinical improvement at the Principal
             Investigator's discretion.

          4. Patients with a medical history of MDD who consistently did not respond significantly
             to electroconvulsive shock therapy (ECT) or had ECT within a year prior to the
             Screening Visit regardless of outcome.

          5. Patients with psychotic depression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nuoyu Huang, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>DOV Pharmaceutical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Psychiatric Care</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Care Studies</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Emotional Fitness</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, LLC</name>
      <address>
        <city>Clementon</city>
        <state>New Jersey</state>
        <zip>08021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Medical Institute</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Medical Institute</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Social Psychiatry Research Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Behavorial Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scranton Medical Institutes</name>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean Arges</name>
      <address>
        <city>Pitesti</city>
        <state>Arges</state>
        <zip>110084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Neurologie si Psihiatrie Oradea</name>
      <address>
        <city>Oradea</city>
        <state>Bihor</state>
        <zip>410154</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinetul Medical Lorentina 2102 S.R.L.</name>
      <address>
        <city>Targoviste</city>
        <state>Dambovita</state>
        <zip>130081</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Corpores Sana Medical SRL</name>
      <address>
        <city>Bucharest</city>
        <zip>010604</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic &quot;Colentina&quot;, Ambulator Specialitate, Sectia Psihiatrie</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alexandru Obregia&quot;, pavilion III</name>
      <address>
        <city>Bucharest</city>
        <zip>041915</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alexandru Obregia&quot;, Pavilion IV</name>
      <address>
        <city>Bucharest</city>
        <zip>041915</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alexandru Obregia&quot;, Pavilion X</name>
      <address>
        <city>Bucharest</city>
        <zip>041915</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Socola&quot;</name>
      <address>
        <city>Lasi</city>
        <zip>700282</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Psihiatrie &quot;Socola&quot;</name>
      <address>
        <city>Lasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean de Urgenta Piatra Neamt</name>
      <address>
        <city>Piatra Neamt</city>
        <zip>610136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Targu Mures</name>
      <address>
        <city>Targu Mures</city>
        <zip>540139</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut za mentalno zdravlje Palmoticeva 37</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut za psihijatriju KCS</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika za neurologiju i psihijatriju</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika za psihijatriju Vojnomedicinske Akademije</name>
      <address>
        <city>Velgrade</city>
        <zip>1100</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2008</study_first_posted>
  <last_update_submitted>December 4, 2008</last_update_submitted>
  <last_update_submitted_qc>December 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Nuoyo Huang, Vice President Clinical Research and Development</name_title>
    <organization>DOV Pharmaceutical, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

